✨
AI Summary
- Retatrutide, Eli Lilly's weight-loss drug, faces a regulatory fight over its classification.
- The controversy centers on two amino acids impacting market exclusivity and competition.
- This regulatory battle could determine the future price and market landscape for retatrutide.